



LATEST NEWS FIDEL CASTRO RETIRES AFTER 49 YEARS IN POWER



### Deals Today

The latest Reuters articles on M&A, IPOs, hedge funds and more

[Subscribe Now](#)



**Unlimited calling  
to your 5 favorite  
people**

You are here: [Home](#) > [News](#) > [Health](#) > Article

[HOME](#)

[BUSINESS & FINANCE](#)

[NEWS](#)

[U.S.](#)

[Politics](#)

[International](#)

[Technology](#)

[Entertainment](#)

[Sports](#)

[Lifestyle](#)

[Oddly Enough](#)

[Environment](#)

[Health](#)

[Science](#)

[Special Coverage](#)

[Video](#)

[Pictures](#)

[You Witness](#)

[Blogs](#)

[Reader Feedback](#)

#### Do More With Reuters

[RSS](#)

[Mobile](#)

[Podcasts](#)

[Newsletters](#)

[You Witness News](#)

#### Partner Services

[CareerBuilder](#)

[Affiliate Network](#)

#### Professional Products

[Support \(Customer Zone\)](#)

[Reuters Media](#)

[Financial Products](#)

## Dr. Dennis Mangano Says On 60 Minutes In February 2008 That Trasylol Should Have Been Recalled As Early As January 2006

powered by BlogBurst

POSTED: Monday, February 18, 2008

FROM BLOG: [Drug Injury Watch](#) - Prescription Drug Side Effects News and Information from Attorney Tom Lamb

The following blog post is from an independent writer and is not connected with Reuters News. The opinions and views expressed herein are those of the author and are not endorsed by Reuters.com.

### Delay By Bayer And FDA Until November 2007, When Trasylol Sales Were "Suspended", Caused 22,000 Excess Deaths Per CBS Report (Posted by Tom Lamb at [DrugInjuryWatch.com](#))

According to [interviews broadcast by CBS Television's 60 Minutes program about Trasylol on February 17, 2008](#), an estimated 22,000 patient lives could have been saved if the FDA had acted quicker to recall Trasylol, Bayer AG's drug used to stem bleeding during open heart surgery.

Trasylol (aprotinin injection) [sales in the U.S. and Canada were suspended by Bayer in early November 2007](#). Trasylol was used to reduce blood loss during coronary artery bypass surgery.

As background, [in mid-February 2006 the FDA announced it was evaluating the safety of Trasylol](#) after new studies had linked this heart surgery drug to higher risks of kidney problems, heart attacks, and strokes. At the end of February 2006 a "Dear Doctor" letter from Bayer regarding Trasylol was posted on Health Canada's MedEffect web site.

Later, the FDA held an advisory committee meeting in September 2006 and, thereafter, [convened another such meeting on September 12, 2007](#) to further discuss Trasylol.

A February 15, 2008 *Reuters* article, "[22,000 died amid delayed Bayer drug recall: doctor](#)", provided these details based on a review of this *60 Minutes* report about Trasylol that had been posted on the CBS News web site in advance of the February 17 broadcast:

Dr. Dennis Mangano, the study's researcher, said during the program that 22,000 lives could have been saved if Trasylol had been taken off the market when he first published his study in January 2006....

He said in the broadcast that Bayer failed to disclose to the FDA during an FDA advisory panel meeting in September 2006 -- at which

[Find a financial adviser](#)

[About Reuters](#)

Mangano's negative findings were discussed -- that the German drugmaker had conducted its own research which confirmed the same dangers established by his study.

The chairman of the FDA advisory panel, Dr. William Hiatt, told 60 Minutes he would have voted to remove Trasyolol from the market had he been informed about Bayer's study, according to the CBS report.

As acknowledged by company spokeswoman Meredith Fischer in the February 15 *Reuters* article, product liability lawsuits have been filed against Bayer on behalf of patients who had died or been seriously injured following the use of Trasyolol during their heart surgery.

[Read more from this blogger at Drug Injury Watch](#) | [Let us know what you think of this feature](#)

---

**Reuters.com:** [Help and Contact Us](#) | [Advertise With Us](#) | [Mobile](#) | [Newsletters](#) | [RSS](#)  | [Interactive TV](#) | [Labs](#) | [Reuters in S](#)  
**Reuters Corporate:** [Copyright](#) | [Disclaimer](#) | [Privacy](#) | [Professional Products](#) | [Professional Products Support](#) | [About Reuters](#) |

**International Editions:** [Africa](#) | [Arabic](#) | [Argentina](#) | [Brazil](#) | [Canada](#) | [Chinese Simplified](#) | [Chinese Traditional](#) | [France](#) | [Gerr](#)  
[Russia](#) | [Spain](#) | [United Kingdom](#) | [United States](#)

Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Reuters journalists are subject to the disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please